Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01880437 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 3 | Dec 15, 2015 | clinicaltrials |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | terminated | Phase 1 / Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Dec 14, 2015 | clinicaltrials |
| NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | terminated | Phase 2 | 56 | Duke UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01260467 | Memantine for Recurrent Glioblastoma | terminated | Phase 2 | 4 | University of RochesterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | terminated | Phase 2 | — | University of CologneOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | terminated | Phase 2 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 1, 2015 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT00313612 | Oxaliplatin and Topotecan in Advance Ovarian Cancer | terminated | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Nov 27, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT01050946 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit(Haplo/Cord) | terminated | Phase 2 | 1 | Medical College of WisconsinOTHER | 0 | Nov 20, 2015 | clinicaltrials |
| NCT01193868 | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy | terminated | Phase 2 | 13 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01577212 | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy(IDEAL-VMAT) | terminated | Phase 2 | 6 | Radboud University Medical CenterOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT01009931 | Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies | terminated | Phase 2 | 1 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 4, 2015 | clinicaltrials |
| NCT01033019 | To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC) | terminated | Phase 2 | 25 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 30, 2015 | clinicaltrials |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 29, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01856322 | Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT00838890 | A Study of BMS-863233 in Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | terminated | Phase 2 | 4 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID) | terminated | Phase 2 | 627 | BiogenINDUSTRY | 23 | Oct 2, 2015 | clinicaltrials |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | terminated | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00923949 | Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01625741 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy(HYDRIC) | terminated | Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00749567 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | terminated | Phase 2 | 13 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT02179567 | Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | terminated | Phase 2 | 26 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy(DOVE-M) | terminated | Phase 2 | 12 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2015source: clinicaltrials